Nesreen S. Ismail

1.7k total citations · 1 hit paper
19 papers, 1.4k citations indexed

About

Nesreen S. Ismail is a scholar working on Molecular Biology, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Nesreen S. Ismail has authored 19 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Nesreen S. Ismail's work include CAR-T cell therapy research (6 papers), Angiogenesis and VEGF in Cancer (6 papers) and Cancer Research and Treatments (5 papers). Nesreen S. Ismail is often cited by papers focused on CAR-T cell therapy research (6 papers), Angiogenesis and VEGF in Cancer (6 papers) and Cancer Research and Treatments (5 papers). Nesreen S. Ismail collaborates with scholars based in United States and Canada. Nesreen S. Ismail's co-authors include Susan M. Dallabrida, Maria A. Rupnick, Elke Pravda, Flávia Cassiola, David Zurakowski, David M. Harris, Frederick J. Schöen, Jey-Hsin Chen, Risto Kerkelä and Tammy F. Chu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Circulation.

In The Last Decade

Nesreen S. Ismail

18 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

2007 814 citations Tammy F. Chu, Maria A. Rupnick et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nesreen S. Ismail United States	10	611	598	459	299	142	19	1.4k
Pablo Colorado United States	12	416 0.7×	998 1.7×	254 0.6×	561 1.9×	646 4.5×	21	2.0k
Johannes Weirather Germany	13	753 1.2×	653 1.1×	509 1.1×	112 0.4×	76 0.5×	28	1.8k
Fabienne Baffert Switzerland	13	151 0.2×	968 1.6×	434 0.9×	223 0.7×	341 2.4×	19	1.5k
Mortimer Korf‐Klingebiel Germany	18	690 1.1×	760 1.3×	142 0.3×	82 0.3×	171 1.2×	25	1.8k
Jasper Koerts Netherlands	17	225 0.4×	826 1.4×	170 0.4×	204 0.7×	284 2.0×	28	1.6k
Wulf Ito Germany	14	249 0.4×	1.0k 1.7×	205 0.4×	167 0.6×	220 1.5×	44	1.7k
Brian Walters United States	8	504 0.8×	634 1.1×	276 0.6×	179 0.6×	56 0.4×	10	1.5k
Wolfgang‐Michael Franz Germany	24	637 1.0×	1.0k 1.7×	282 0.6×	91 0.3×	91 0.6×	60	2.1k
Mary Jo Mulligan‐Kehoe United States	18	195 0.3×	616 1.0×	158 0.3×	227 0.8×	188 1.3×	26	1.5k
Samuel Unzek United States	9	434 0.7×	550 0.9×	216 0.5×	93 0.3×	94 0.7×	36	1.5k

Countries citing papers authored by Nesreen S. Ismail

Since Specialization

Citations

This map shows the geographic impact of Nesreen S. Ismail's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nesreen S. Ismail with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nesreen S. Ismail more than expected).

Fields of papers citing papers by Nesreen S. Ismail

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nesreen S. Ismail. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nesreen S. Ismail. The network helps show where Nesreen S. Ismail may publish in the future.

Co-authorship network of co-authors of Nesreen S. Ismail

This figure shows the co-authorship network connecting the top 25 collaborators of Nesreen S. Ismail. A scholar is included among the top collaborators of Nesreen S. Ismail based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nesreen S. Ismail. Nesreen S. Ismail is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Nirschl, Christopher J., Daniel J. Hicklin, Nesreen S. Ismail, et al.. (2022). Abstract 2054: WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives anti-tumor immunity by activating tumor infiltrating CD8+ T cells. Cancer Research. 82(12_Supplement). 2054–2054.

Tyagi, Ethika, Dan Hicklin, Nesreen S. Ismail, et al.. (2021). 723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models. SHILAP Revista de lepidopterología. A752–A752. 3 indexed citations

Steiner, Philipp, Dan Hicklin, Nesreen S. Ismail, et al.. (2021). Abstract 1716: WTX-330, a conditionally activated IL-12 INDUKINE, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models. Cancer Research. 81(13_Supplement). 1716–1716. 4 indexed citations

Steiner, Philipp, Daniel J. Hicklin, Randi Isaacs, et al.. (2021). Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates. Blood. 138(Supplement 1). 2258–2258. 9 indexed citations

Morris, Kristin, Daniel J. Hicklin, Nesreen S. Ismail, et al.. (2021). 715 WTX-330 is an IL-12 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models. SHILAP Revista de lepidopterología. A744–A744. 2 indexed citations

Salmerón, Andrés, Daniel J. Hicklin, Nesreen S. Ismail, et al.. (2021). Abstract 1723: WTX-124 is an IL-2 pro-drug conditionally activated in tumors and able to induce complete regressions in mouse tumor models. Cancer Research. 81(13_Supplement). 1723–1723. 1 indexed citations

Nirschl, Christopher J., Daniel J. Hicklin, Nesreen S. Ismail, et al.. (2021). 718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models. SHILAP Revista de lepidopterología. A747–A747. 3 indexed citations

Lerner, Lorena, Nianjun Tao, Brian Krieger, et al.. (2015). Abstract 1153: Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody. Cancer Research. 75(15_Supplement). 1153–1153. 4 indexed citations

Miklas, Jason W., Susan M. Dallabrida, Lewis A. Reis, et al.. (2013). QHREDGS Enhances Tube Formation, Metabolism and Survival of Endothelial Cells in Collagen-Chitosan Hydrogels. PLoS ONE. 8(8). e72956–e72956. 38 indexed citations

10.

Sunshine, Sarah B., Susan M. Dallabrida, Ellen M. Durand, et al.. (2012). Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proceedings of the National Academy of Sciences. 109(28). 11306–11311. 40 indexed citations

11.

Mayer, Erik, Susan M. Dallabrida, Maria A. Rupnick, et al.. (2011). Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans. Hypertension. 58(1). 85–92. 39 indexed citations

12.

Bai, Ailin, Kristan Meetze, William M. Winston, et al.. (2010). GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling. Cancer Research. 70(19). 7630–7639. 123 indexed citations

13.

Dallabrida, Susan M., Nesreen S. Ismail, Zohreh Amoozgar, et al.. (2010). Photocrosslinkable chitosan modified with angiopoietin‐1 peptide, QHREDGS, promotes survival of neonatal rat heart cells. Journal of Biomedical Materials Research Part A. 95A(1). 105–117. 37 indexed citations

14.

Ismail, Nesreen S., Elke Pravda, Dan Li, Shou‐Ching Shih, & Susan M. Dallabrida. (2010). Angiopoietin-1 Reduces H2O2-Induced Increases in Reactive Oxygen Species and Oxidative Damage to Skin Cells. Journal of Investigative Dermatology. 130(5). 1307–1317. 21 indexed citations

15.

Mihic, Anton, Lewis A. Reis, Susan M. Dallabrida, et al.. (2010). Hydrogels modified with QHREDGS peptide support cardiomyocyte survival in vitro and after sub-cutaneous implantation. Soft Matter. 6(20). 5089–5089. 26 indexed citations

16.

Dallabrida, Susan M., Nesreen S. Ismail, Elke Pravda, et al.. (2008). Integrin binding angiopoietin‐1 monomers reduce cardiac hypertrophy. The FASEB Journal. 22(8). 3010–3023. 39 indexed citations

17.

Chu, Tammy F., Maria A. Rupnick, Risto Kerkelä, et al.. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet. 370(9604). 2011–2019. 814 indexed citations breakdown →

18.

Dallabrida, Susan M., Nesreen S. Ismail, Elke Pravda, et al.. (2007). Abstract 1505: Sunitinib-Induced Cardiotoxicity is Mediated in Part via Direct Effects on Cardiac Myocytes and Smooth Muscle Cells. Circulation. 116(suppl_16). 3 indexed citations

19.

Dallabrida, Susan M., et al.. (2005). Angiopoietin-1 Promotes Cardiac and Skeletal Myocyte Survival Through Integrins. Circulation Research. 96(4). e8–24. 169 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact